Breaking News

Juniper Pharma Services Expands Tablet Mfg. Capabilities

June 21, 2016

Adds RoTab tablet press by kg-pharma

Juniper Pharma Services has expanded its tablet manufacturing capabilities with the purchase and validation of an additional tablet press.The new RoTab tablet press by kg-pharma is designed for batch sizes from 50g to 50kg and allows Juniper to produce up to 42,000 tablets per hour, and to produce single and bi-layer tablets in multiple tooling formats.
 
Ian Lafferty, vice president of operations at Juniper Pharma Services, said, “The installation of this additional tablet press machine takes both our capability to produce different tablet types, and our output capacity, to a new level. We continue to expand our support to pharmaceutical and biotechnology companies across the globe, especially to those with significant formulation challenges requiring the integrated skills of a problem-to-solution minded development team.”
 
Juniper Pharma Services, with GMP clinical manufacturing capabilities based in Nottingham, develops and produces oral and topical drug products for clinical trials.

Related Contract Manufacturing:

Related Compliance:

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research